CJC-1295 & Ipamorelin in Canada: A Researcher's Guide to Growth Hormone Secretagogues in 2026

Among the most actively studied peptide combinations in current research, CJC-1295 and Ipamorelin have drawn sustained scientific interest for their complementary roles in modulating the growth hormone (GH) axis. For Canadian researchers exploring GH secretagogue biology, this pairing offers a dual-pathway approach that has generated a growing body of preclinical and translational data. This guide covers the mechanism, research findings, regulatory context, and what to look for in quality research peptides Canada suppliers.

What Are CJC-1295 and Ipamorelin?

CJC-1295 is a synthetic analogue of growth hormone-releasing hormone (GHRH), the endogenous hypothalamic signal that stimulates the pituitary to secrete GH. The version most frequently studied in research contexts is CJC-1295 without DAC (also known as Modified GRF 1-29), which produces a shorter, more physiologically pulsatile GH release pattern compared to the DAC-conjugated version.

Ipamorelin is a selective growth hormone secretagogue (GHS) that acts through the ghrelin receptor (GHS-R1a). Unlike earlier GH secretagogues such as GHRP-6, Ipamorelin is notable in preclinical studies for producing robust GH responses with comparatively fewer off-target hormonal effects on cortisol and prolactin — properties that have made it a favoured research tool for studying the GH secretagogue pathway in isolation.

Together, CJC-1295 and Ipamorelin engage two distinct but converging pathways — GHRH-receptor stimulation and ghrelin-receptor stimulation — to produce synergistic GH pulse amplitudes. Research in animal models has reported combined GH pulse amplitudes of 3 to 5 times baseline, compared to roughly 1.5 to 2 times baseline with either compound used alone.

The Science: What Peptide Research Has Found

Synergistic GH Axis Stimulation

The central research interest in the CJC-1295 and Ipamorelin combination lies in their complementary mechanisms. CJC-1295 (without DAC) supports pulsatile GHRH-pathway signalling, while Ipamorelin activates GHS-R1a through the ghrelin pathway. Preclinical data consistently shows that GHRH and GHS agonists together produce superadditive GH release — a finding that has guided research into how the hypothalamic-pituitary axis can be studied using synthetic ligands.

Studies have reported that administering CJC-1295 alone can increase plasma GH concentrations by 2 to 10 times over baseline for periods extending several days. Adding Ipamorelin to this baseline amplifies the pulsatile peak, making the combination particularly useful for researchers examining GH secretion kinetics.

IGF-1, Sleep, and Body Composition Research

Downstream from GH stimulation, insulin-like growth factor 1 (IGF-1) is the primary mediator of many GH-associated biological effects. Research in aged rodent models has explored whether GH secretagogue combinations can restore age-related declines in IGF-1 signalling. A 2025 study in Growth Hormone and IGF Research examining circadian timing in such models found that administration during the early sleep phase produced approximately 40% greater IGF-1 elevation compared to daytime dosing — reinforcing the relevance of GH's natural nocturnal release pattern to research design.

GH plays a well-characterized role in lipid and carbohydrate metabolism. Research exploring GH secretagogue combinations has examined their downstream influence on lipid oxidation and glucose homeostasis, particularly in metabolic disorder models. Similarly, the link between GH, slow-wave sleep architecture, and recovery biology has made CJC-1295 and Ipamorelin subjects of interest in sleep and circadian rhythm research.

Selectivity: Why Ipamorelin Stands Out

A key reason Ipamorelin attracted attention in early peptide research was its selectivity profile. Experimental studies demonstrated robust GH-releasing activity without the cortisol, prolactin, or appetite-stimulating effects seen with less selective GH secretagogues. This makes Ipamorelin a useful research comparator when investigators need to isolate GH axis effects from broader neuroendocrine responses.

CJC-1295 & Ipamorelin in Canada: The Regulatory Landscape

Understanding the regulatory status of research peptides in Canada is essential for any researcher working with these compounds.

Health Canada does not currently list CJC-1295 or Ipamorelin as scheduled controlled substances under the Controlled Drugs and Substances Act. However, Health Canada has issued public warnings advising against the use of unauthorized injectable peptide products for health or wellness purposes, emphasizing that no such products have received market authorization for therapeutic use in Canada.

This distinction is important: the regulatory warnings target unapproved therapeutic use, not legitimate in-vitro or preclinical peptide research. In Canada, research institutions, licensed laboratories, and qualified researchers can acquire and work with these peptides under the broader framework governing research chemicals and unapproved compounds, provided their use remains within a bona fide research context.

Researchers should always consult their institution's biosafety officer or research ethics board, and ensure they are operating in compliance with applicable provincial and federal guidelines. Helix Core Labs supplies these compounds strictly for research use and does not support or encourage any extra-research application.

CJC-1295 Without DAC vs. CJC-1295 With DAC: Which Is Studied More?

Researchers new to CJC-1295 often encounter both the DAC (Drug Affinity Complex) and non-DAC versions. The key difference:

• CJC-1295 without DAC (Modified GRF 1-29): Half-life of approximately 30 minutes. Produces short, pulsatile GH release — more closely mimicking endogenous GHRH signalling. Commonly paired with Ipamorelin in research protocols examining acute GH dynamics.
• CJC-1295 with DAC: Extended half-life of up to 8 days due to albumin-binding technology. Produces a more sustained elevation in GH. Used in research contexts where chronic GH axis stimulation is the variable of interest.

For research designs intended to study physiological-style GH pulses alongside Ipamorelin, CJC-1295 without DAC is the more frequently cited choice in the scientific literature.

What Canadian Researchers Are Exploring in 2026

Interest in GH secretagogue research in Canada aligns with several active areas of investigation in 2026:

• Aging and sarcopenia models: GH axis decline is a central feature of biological aging. Research using CJC-1295 and Ipamorelin in aged animal models continues to examine whether restoring GH pulsatility can influence muscle protein synthesis and body composition.
• Sleep and recovery biology: The relationship between GH release and slow-wave sleep is an established area; secretagogue research is helping investigators understand the bidirectional link between sleep architecture and GH axis activity.
• Metabolic health: Research into GH's role in adipose tissue metabolism and glucose regulation has made GH secretagogue combinations relevant to metabolic syndrome research.
• Pituitary function studies: CJC-1295 and Ipamorelin together serve as pharmacological tools for mapping pituitary responsiveness in various experimental conditions.

Sourcing Quality CJC-1295 & Ipamorelin for Research

Research data is only as reliable as the compounds used to generate it. When sourcing CJC-1295 and Ipamorelin for peptide research in Canada, researchers should evaluate suppliers on the following criteria:

Purity and Certificate of Analysis (CoA)

A reputable supplier provides a batch-specific Certificate of Analysis from an independent third-party laboratory. For research-grade peptides, purity of ≥98% is the standard minimum, with many Canadian research institutions expecting ≥99%. The CoA should confirm identity via HPLC and mass spectrometry.

Lyophilization and Stability

Research-grade CJC-1295 and Ipamorelin are supplied in lyophilized (freeze-dried) form, which maximizes shelf stability and minimizes degradation risk during shipping. Suppliers should maintain cold-chain logistics and clearly indicate storage requirements.

Transparency and Research Focus

A quality supplier clearly states that products are for research use only, provides complete product information, and does not make therapeutic or health claims. The ability to supply documentation, answer technical questions, and demonstrate familiarity with research applications is a strong indicator of a credible source.

At Helix Core Labs, our research peptides Canada catalog is built around these standards — offering high-purity, lyophilized CJC-1295 and Ipamorelin backed by independent third-party CoAs, designed for researchers who need compounds they can rely on.

Explore the Helix Core Labs Catalog

If you're conducting research into growth hormone secretagogue biology, the CJC-1295 and Ipamorelin combination represents one of the most well-characterized dual-pathway tools available. Helix Core Labs is committed to supporting Canadian peptide researchers with rigorously tested, high-purity compounds and transparent documentation.

Browse our full catalog at helixcorelabs.ca to explore our current inventory of research peptides, including CJC-1295 (without DAC), Ipamorelin, and a range of other compounds relevant to GH axis, metabolic, and recovery biology research.

All products sold by Helix Core Labs are intended for research use only and are not approved for human or veterinary use. This article is for informational purposes only and does not constitute medical advice.